

Guideline Page and Request	Panel Discussion/References	Vote			
		YES	NO	ABSTAIN	ABSENT
(BCC-3) and (BCC-4) Internal request: Institutional Review comment requesting broader phrasing to include the class of drugs: "hedgehog inhibitor drugs".	<p>Based on discussion of the data supporting the FDA approval of sonidegib and reported in primary manuscripts listed below, the panel consensus supported replacing "vismodegib" with the broader phrase "a hedgehog pathway inhibitor", along with a new footnote: "Current FDA-approved hedgehog pathway inhibitors include vismodegib and sonidegib"</p> <ul style="list-style-type: none"> Prescribing information: ODOMZO (sonidegib) capsules, for oral use. 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf. Accessed October 13, 2015. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomized, double-blind phase 2 trial. Lancet Oncol 2015;16:716-728. 	13	0	0	15
(BCC-B) Internal request: Institutional Review comment requesting to include interferon injections for patients with low-risk, superficial basal cell skin cancer	<p>Data from non-comparative open-label studies and a double-blind randomized trial with placebo control showed that intralesional interferon alfa-2b can be effective for treating low-risk, superficial basal cell skin cancer (see references below). The panel members discussed that this approach was generally not used at their institutions, however, because of expense, impractical treatment regimen (injections 3 times a week for 3 weeks), and associated flu-like side effects. Based on their discussion the panel consensus was to not include interferon injections for patients with low-risk, superficial basal cell skin cancer.</p> <ul style="list-style-type: none"> Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23:694-700. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 2006; 54:1033-1038. Chimenti S, Peris K, Di Cristofaro S, et al. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 1995; 190:214-217. 	4	6	3	15